Takahiro Nunokawa

Takahiro Nunokawa

Auto-generated profile, based on publicly available information

Takahiro Nunokawa

Department of Internal Medicine, Tama Nambu Chiiki Hospital, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2015 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
TNT Nunokawa
T Nunokawa
NYN Yokogawa
N Yokogawa
KSK Shimada
K Shimada
KEK Enatsu
K Enatsu
SSS Sugii
S Sugii
Objectives: The aim of this study was to assess the use of muscle biopsy for histopathological confirmation of small vessel vasculitis (SVV) or medium vessel vasculitis (MVV). Method: Muscle biopsies were performed for all consecutive cases of suspected SVV or MVV seen at Tokyo Metropolitan Tama Medical Centre between February 2012 and May 2014 except those for which a skin or renal biopsy was indicated. Results: Forty-nine patients underwent muscle biopsies. All patients were followed for a minimum of 6 months. Diagnosis of SVV or MVV was made in 35 patients. An unrelated condition was diagnosed in 11 patients and no diagnoses were made in three patients. Of the 35 patients in whom SVV or MVV was diagnosed, positive muscle biopsies were obtained in 20 patients [15 microscopic polyangiitis (MPA), three polyarteritis nodosa (PAN), and two eosinophilic granulomatosis with polyangiitis (EGPA)], while other findings led to the same diagnosis in 15 (seven MPA, four GPA, three PAN, and one rheumatoid vasculitis). The sensitivity of the muscle biopsy was 57% [20/35; 95% confidence interval (CI) 50–57]. Of 13 patients presenting with peripheral neuropathy, the muscle biopsy demonstrated vasculitis in nine patients, with 75% sensitivity (9/12; 95% CI 69–75). There were no complications in the procedure apart from delayed wound healing in one patient. Conclusions: Muscle biopsy is a safe method that offers a high diagnostic yield for SVV or MVV, especially in patients with vasculitic neuropathy.

25 June 2019 in Rheumatology
Verified
Journal Article
Open access
YKYuko Kaneko
Yuko Kaneko
TNTakahiro Nunokawa
Takahiro Nunokawa
YTYoshinori Taniguchi
Yoshinori Taniguchi
YYYukie Yamaguchi
Yukie Yamaguchi
TGTakahisa Gono
Takahisa Gono
YKYoshie Kawahara
Yoshie Kawahara
Objective: To clarify the incidence, risk factors, and impact of malignancy in patients with PM/DM-associated interstitial lung disease (ILD). Methods: This study used data from 497 patients with PM/DM-associated ILD enrolled in a multicentre, retrospective and prospective cohort of incident cases. Cancer-associated myositis (CAM) was defined as malignancy diagnosed within 3 years before or after PM/DM diagnosis. Demographic and clinical information was recorded at the time of diagnosis, and data about the occurrence of mortality and malignancy was collected. Results: CAM was identified in 32 patients with PM/DM-associated ILD (6.4%). Patients with CAM were older (64 vs 55 years, P < 0.001), presented with arthritis less frequently (24% vs 49%, P = 0.01), and showed a lower level of serum Krebs von den Lungen-6 (687 vs 820 IU/l, P = 0.03) than those without CAM. The distribution of myositis-specific autoantibodies, including anti-melanoma differentiation–associated gene 5, anti-aminoacyl tRNA synthetase, and anti-transcriptional intermediary factor 1-γ antibodies, did not differ between the groups. Survival analysis demonstrated that CAM patients had a poorer survival than non-CAM patients (P = 0.006), primarily due to excess deaths by concomitant malignancy, while mortality due to ILD-related respiratory failure was similar between the groups (P = 0.51). Conclusion: Concomitant malignancy can occur in patients with PM/DM-associated ILD, and has significant impact on mortality. Older age, lack of arthritis, and a lower level of serum Krebs von den Lungen-6 at diagnosis are predictors of concomitant malignancy.

2 December 2022 in Medicine
Verified
Journal Article
Open access
TKTakuya Kakutani
Takuya Kakutani
TNTakahiro Nunokawa
Takahiro Nunokawa
NCNaofumi Chinen
Naofumi Chinen
YTYotaro Tamai
Yotaro Tamai
Rationale: Thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome are nonmalignant but life-threatening systemic inflammatory disorders. However, many patients are refractory to treatment, resulting in significant morbidity and mortality. Additionally, established treatment options are unavailable. Therefore, we present 2 cases of adults with the iMCD-TAFRO syndrome refractory to initial treatment but responded to Janus kinase (JAK) inhibitors with ruxolitinib. The report reveals that these rare adult cases of the refractory and treatment-resistant iMCD-TAFRO syndrome can be treated using JAK inhibitors. Patient concerns: Case 1 is a 36-year-old previously healthy male patient who presented with fever and general fatigue for 2 weeks. Case 2 is a 42-year-old previously healthy female patient who presented with fever and general fatigue. Diagnosis: The diagnosis met the 2015 criteria for TAFRO syndrome, as determined by All Japan TAFRO Syndrome Research Group in the Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. Interventions: Treatment with tocilizumab and several immunosuppressants were ineffective. So, we performed ruxolitinib. Outcomes: Each patient received ruxolitinib, the general condition improved, and CRP levels decreased. Lessons: These cases showed that ruxolitinib was effective for treatment-resistant/ refractory TAFRO syndrome. Further prospective studies are needed on using ruxolitinib with a small number of cases.

9 November 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TNTakahiro Nunokawa
Takahiro Nunokawa
NCNaofumi Chinen
Naofumi Chinen
KSKota Shimada
Kota Shimada
MKMakiko Kimura
Makiko Kimura
MTMutsuto Tateishi
Mutsuto Tateishi
MSMakoto Sugihara
Makoto Sugihara

1 November 2021 in Internal Medicine
Verified
Journal Article
Open access
PDF file
EKEisuke Kanematsu
Eisuke Kanematsu
TNTakahiro Nunokawa
Takahiro Nunokawa
NCNaofumi Chinen
Naofumi Chinen
AKAkio Komatsu
Akio Komatsu
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

1 March 2023 in Internal Medicine
Verified
Journal Article
Open access
PDF file
SOShushi Okuno
Shushi Okuno
TNTakahiro Nunokawa
Takahiro Nunokawa
NCNaofumi Chinen
Naofumi Chinen
SSShino Sogabe
Shino Sogabe
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.